Gynecologic Cancers
November 10
6 min read
Can patients with platinum-resistant ovarian cancer treated with taxane therapy benefit from receiving relacorilant after a taxane? A new subgroup analysis from the phase III ROSELLA trial suggests the answer may be yes. The analysis, presented at the 2026 ASCO Annual Meeting, focused on prior taxane use because previous exposure may influence outcomes with subsequent taxane-based regimens; nearly all patients in ROSELLA had previously received a taxane.